<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35178738</PMID><DateCompleted><Year>2022</Year><Month>04</Month><Day>19</Day></DateCompleted><DateRevised><Year>2023</Year><Month>03</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1531-8249</ISSN><JournalIssue CitedMedium="Internet"><Volume>91</Volume><Issue>5</Issue><PubDate><Year>2022</Year><Month>May</Month></PubDate></JournalIssue><Title>Annals of neurology</Title><ISOAbbreviation>Ann Neurol</ISOAbbreviation></Journal><ArticleTitle>Imaging Net Retrograde Axonal Transport In Vivo: A Physiological Biomarker.</ArticleTitle><Pagination><StartPage>716</StartPage><EndPage>729</EndPage><MedlinePgn>716-729</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/ana.26329</ELocationID><Abstract><AbstractText Label="OBJECTIVE">The objective of this study is to develop a novel method for monitoring the integrity of motor neurons in vivo by quantifying net retrograde axonal transport.</AbstractText><AbstractText Label="METHODS">The method uses single photon emission computed tomography to quantify retrograde transport to spinal cord of tetanus toxin fragment C (<sup>125</sup> I-TTC) following intramuscular injection. We characterized the transport profiles in 3 transgenic mouse models carrying amyotrophic lateral sclerosis (ALS)-associated genes, aging mice, and SOD1<sup>G93A</sup> transgenic mice following CRISPR/Cas9 gene editing. Lastly, we studied the effect of prior immunization of tetanus toxoid on the transport profile of TTC.</AbstractText><AbstractText Label="RESULTS">This technique defines a quantitative profile of net retrograde axonal transport of TTC in living mice. The profile is distinctly abnormal in transgenic SOD1<sup>G93A</sup> mice as young as 65&#x2009;days (presymptomatic) and worsens with disease progression. Moreover, this method detects a distinct therapeutic benefit of gene editing in transgenic SOD1<sup>G93A</sup> mice well before other clinical parameters (eg, grip strength) show improvement. Symptomatic transgenic PFN1<sup>C71G/C71G</sup> ALS mice display gross reductions in net retrograde axonal transport, which is also disturbed in asymptomatic mice harboring a human C9ORF72 transgene with an expanded GGGGCC repeat motif. In wild-type mice, net retrograde axonal transport declines with aging. Lastly, prior immunization with tetanus toxoid does not preclude use of this assay.</AbstractText><AbstractText Label="INTERPRETATION">This assay of net retrograde axonal transport has broad potential clinical applications and should be particularly valuable as a physiological biomarker that permits early detection of benefit from potential therapies for motor neuron diseases. ANN NEUROL 2022;91:716-729.</AbstractText><CopyrightInformation>&#xa9; 2022 The Authors. Annals of Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Lee</LastName><ForeName>Pin-Tsun Justin</ForeName><Initials>PJ</Initials><Identifier Source="ORCID">0000-0002-3444-9696</Identifier><AffiliationInfo><Affiliation>Department of Neurology, University of Massachusetts Chan Medical School, Worcester, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Kennedy</LastName><ForeName>Zachary</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Massachusetts Chan Medical School, Worcester, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>RNA Therapeutics Institute, University of Massachusetts Chan Medical School, Worcester, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Yuzhen</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Radiology, University of Massachusetts Chan Medical School, Worcester, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Yimeng</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>VIR Biotechnology, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cefaliello</LastName><ForeName>Carolina</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-9117-6719</Identifier><AffiliationInfo><Affiliation>Department of Neurology, University of Massachusetts Chan Medical School, Worcester, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Uyan</LastName><ForeName>&#xd6;zg&#xfc;n</ForeName><Initials>&#xd6;</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Massachusetts Chan Medical School, Worcester, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Song</LastName><ForeName>Chun-Qing</ForeName><Initials>CQ</Initials><AffiliationInfo><Affiliation>RNA Therapeutics Institute, University of Massachusetts Chan Medical School, Worcester, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Program in Molecular Medicine, Department of Molecular, Cell, and Cancer Biology, and Li Weibo Institute for Rare Disease Research, University of Massachusetts Chan Medical School, Worcester, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Godinho</LastName><ForeName>Bruno Miguel da Cruz</ForeName><Initials>BMC</Initials><AffiliationInfo><Affiliation>RNA Therapeutics Institute, University of Massachusetts Chan Medical School, Worcester, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Program in Molecular Medicine, Department of Molecular, Cell, and Cancer Biology, and Li Weibo Institute for Rare Disease Research, University of Massachusetts Chan Medical School, Worcester, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Zuoshang</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Biochemistry and Molecular Pharmacology, University of Massachusetts Chan Medical School, Worcester, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rusckowski</LastName><ForeName>Mary</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Radiology, University of Massachusetts Chan Medical School, Worcester, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xue</LastName><ForeName>Wen</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>RNA Therapeutics Institute, University of Massachusetts Chan Medical School, Worcester, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Program in Molecular Medicine, Department of Molecular, Cell, and Cancer Biology, and Li Weibo Institute for Rare Disease Research, University of Massachusetts Chan Medical School, Worcester, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brown</LastName><ForeName>Robert H</ForeName><Initials>RH</Initials><Suffix>Jr</Suffix><Identifier Source="ORCID">0000-0001-6062-1528</Identifier><AffiliationInfo><Affiliation>Department of Neurology, University of Massachusetts Chan Medical School, Worcester, MA, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>RO1-NS088689</GrantID><Acronym>NH</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001453</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS118145</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS088689</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1-TR001453</GrantID><Acronym>NH</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>5R01NS101895</GrantID><Acronym>NH</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS101895</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>03</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Ann Neurol</MedlineTA><NlmUniqueID>7707449</NlmUniqueID><ISSNLinking>0364-5134</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C495738">PFN1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051304">Profilins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013745">Tetanus Toxoid</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D013482">Superoxide Dismutase</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D000072105">Superoxide Dismutase-1</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001370" MajorTopicYN="Y">Axonal Transport</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051304" MajorTopicYN="N">Profilins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013116" MajorTopicYN="N">Spinal Cord</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013482" MajorTopicYN="N">Superoxide Dismutase</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000072105" MajorTopicYN="N">Superoxide Dismutase-1</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013745" MajorTopicYN="N">Tetanus Toxoid</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>Nothing to report.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>2</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>11</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>2</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>2</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>4</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>2</Month><Day>18</Day><Hour>5</Hour><Minute>54</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35178738</ArticleId><ArticleId IdType="pmc">PMC9313858</ArticleId><ArticleId IdType="doi">10.1002/ana.26329</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Adalbert R, Coleman MP. Review: axon pathology in age&#x2010;related neurodegenerative disorders. Neuropathol Appl Neurobiol 2013;39:90&#x2013;108.</Citation><ArticleIdList><ArticleId IdType="pubmed">23046254</ArticleId></ArticleIdList></Reference><Reference><Citation>Breuer AC, Lynn MP, Atkinson MB, et al. Fast axonal transport in amyotrophic lateral sclerosis: an intra&#x2010;axonal organelle traffic analysis. Neurology 1987;37:738&#x2013;748.</Citation><ArticleIdList><ArticleId IdType="pubmed">2437494</ArticleId></ArticleIdList></Reference><Reference><Citation>Sasaki S, Iwata M. Impairment of fast axonal transport in the proximal axons of anterior horn neurons in amyotrophic lateral sclerosis. Neurology 1996;47:535&#x2013;540.</Citation><ArticleIdList><ArticleId IdType="pubmed">8757033</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang B, Tu P, Abtahian F, et al. Neurofilaments and orthograde transport are reduced in ventral root axons of transgenic mice that express human SOD1 with a G93A mutation. J Cell Biol 1997;139:1307&#x2013;1315.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2140205</ArticleId><ArticleId IdType="pubmed">9382875</ArticleId></ArticleIdList></Reference><Reference><Citation>Warita H, Itoyama Y, Abe K. Selective impairment of fast anterograde axonal transport in the peripheral nerves of asymptomatic transgenic mice with a G93A mutant SOD1 gene. Brain Res 1999;819:120&#x2013;131.</Citation><ArticleIdList><ArticleId IdType="pubmed">10082867</ArticleId></ArticleIdList></Reference><Reference><Citation>Williamson T, Cleveland D. Slowing of axonal transport is a very early event in the toxicity of ALS&#x2010;linked SOD1 mutant to motor neurons. Nat Neurosci 1999;1:50&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pubmed">10195180</ArticleId></ArticleIdList></Reference><Reference><Citation>Ligon LA, LaMonte BH, Wallace KE, et al. Mutant superoxide dismutase disrupts cytoplasmic dynein in motor neurons. Neuroreport 2005;16:533&#x2013;536.</Citation><ArticleIdList><ArticleId IdType="pubmed">15812301</ArticleId></ArticleIdList></Reference><Reference><Citation>Bosco DA, Morfini G, Karabacak NM, et al. Wild&#x2010;type and mutant SOD1 share an aberrant conformation and a common pathogenic pathway in ALS. Nat Neurosci 2010;13:1396&#x2013;1403.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2967729</ArticleId><ArticleId IdType="pubmed">20953194</ArticleId></ArticleIdList></Reference><Reference><Citation>Bilsland LG, Sahai E, Kelly G, et al. Deficits in axonal transport precede ALS symptoms in vivo. Proc Natl Acad Sci U S A 2010;107:20523&#x2013;20528.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2996651</ArticleId><ArticleId IdType="pubmed">21059924</ArticleId></ArticleIdList></Reference><Reference><Citation>Magrane J, Sahawneh MA, Przedborski S, et al. Mitochondrial dynamics and bioenergetic dysfunction is associated with synaptic alterations in mutant SOD1 motor neurons. J Neurosci 2012;32:229&#x2013;242.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3566782</ArticleId><ArticleId IdType="pubmed">22219285</ArticleId></ArticleIdList></Reference><Reference><Citation>Magrane J, Cortez C, Gan WB, Manfredi G. Abnormal mitochondrial transport and morphology are common pathological denominators in SOD1 and TDP43 ALS mouse models. Hum Mol Genet 2014;23:1413&#x2013;1424.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3929084</ArticleId><ArticleId IdType="pubmed">24154542</ArticleId></ArticleIdList></Reference><Reference><Citation>Morfini GA, Bosco DA, Brown H, et al. Inhibition of fast axonal transport by pathogenic SOD1 involves activation of p38 MAP kinase. PLoS One 2013;8:e65235.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3680447</ArticleId><ArticleId IdType="pubmed">23776455</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang W, Li L, Lin WL, et al. The ALS disease&#x2010;associated mutant TDP&#x2010;43 impairs mitochondrial dynamics and function in motor neurons. Hum Mol Genet 2013;22:4706&#x2013;4719.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3820133</ArticleId><ArticleId IdType="pubmed">23827948</ArticleId></ArticleIdList></Reference><Reference><Citation>Alami NH, Smith RB, Carrasco MA, et al. Axonal transport of TDP&#x2010;43 mRNA granules is impaired by ALS&#x2010;causing mutations. Neuron 2014;81:536&#x2013;543.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3939050</ArticleId><ArticleId IdType="pubmed">24507191</ArticleId></ArticleIdList></Reference><Reference><Citation>Clark JA, Southam KA, Blizzard CA, et al. Axonal degeneration, distal collateral branching and neuromuscular junction architecture alterations occur prior to symptom onset in the SOD1(G93A) mouse model of amyotrophic lateral sclerosis. J Chem Neuroanat 2016;76:35&#x2013;47.</Citation><ArticleIdList><ArticleId IdType="pubmed">27038603</ArticleId></ArticleIdList></Reference><Reference><Citation>Landers JE, Melki J, Meininger V, et al. Reduced expression of the kinesin&#x2010;associated protein 3 (KIFAP3) gene increases survival in sporadic amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A 2009;106:9004&#x2013;9009.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2683883</ArticleId><ArticleId IdType="pubmed">19451621</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu CH, Fallini C, Ticozzi N, et al. Mutations in the profilin 1 gene cause familial amyotrophic lateral sclerosis. Nature 2012;488:499&#x2013;503.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3575525</ArticleId><ArticleId IdType="pubmed">22801503</ArticleId></ArticleIdList></Reference><Reference><Citation>Kenna KP, van Doormaal PT, Dekker AM, et al. NEK1 variants confer susceptibility to amyotrophic lateral sclerosis. Nat Genet 2016;48:1037&#x2013;1042.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5560030</ArticleId><ArticleId IdType="pubmed">27455347</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith BN, Ticozzi N, Fallini C, et al. Exome&#x2010;wide rare variant analysis identifies TUBA4A mutations associated with familial ALS. Neuron 2014;84:324&#x2013;331.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4521390</ArticleId><ArticleId IdType="pubmed">25374358</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang F, Strom AL, Fukada K, et al. Interaction between familial amyotrophic lateral sclerosis (ALS)&#x2010;linked SOD1 mutants and the dynein complex. J Biol Chem 2007;282:16691&#x2013;16699.</Citation><ArticleIdList><ArticleId IdType="pubmed">17403682</ArticleId></ArticleIdList></Reference><Reference><Citation>Strom AL, Shi P, Zhang F, et al. Interaction of amyotrophic lateral sclerosis (ALS)&#x2010;related mutant copper&#x2010;zinc superoxide dismutase with the dynein&#x2010;dynactin complex contributes to inclusion formation. J Biol Chem 2008;283:22795&#x2013;22805.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2504878</ArticleId><ArticleId IdType="pubmed">18515363</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor JP, Brown RH Jr, Cleveland DW. Decoding ALS: from genes to mechanism. Nature 2016;539:197&#x2013;206.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5585017</ArticleId><ArticleId IdType="pubmed">27830784</ArticleId></ArticleIdList></Reference><Reference><Citation>Altman T, Ionescu A, Ibraheem A, et al. Axonal TDP&#x2010;43 condensates drive neuromuscular junction disruption through inhibition of local synthesis of nuclear encoded mitochondrial proteins. Nat Commun 2021;12:6914.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8617040</ArticleId><ArticleId IdType="pubmed">34824257</ArticleId></ArticleIdList></Reference><Reference><Citation>Benn SC, Ay I, Bastia E, et al. Tetanus toxin fragment C fusion facilitates protein delivery to CNS neurons from cerebrospinal fluid in mice. J Neurochem 2005;95:1118&#x2013;1131.</Citation><ArticleIdList><ArticleId IdType="pubmed">16271047</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogers TB, Snyder SH. High affinity binding of tetanus toxin to mammalian cell membranes. J Biol Chem 1981;256:2402&#x2013;2407.</Citation><ArticleIdList><ArticleId IdType="pubmed">6257717</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang C, Danielson EW, Qiao T, et al. Mutant PFN1 causes ALS phenotypes and progressive motor neuron degeneration in mice by a gain of toxicity. Proc Natl Acad Sci U S A 2016;113:E6209&#x2013;E6218.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5068285</ArticleId><ArticleId IdType="pubmed">27681617</ArticleId></ArticleIdList></Reference><Reference><Citation>Peters OM, Cabrera GT, Tran H, et al. Human C9ORF72 hexanucleotide expansion reproduces RNA foci and dipeptide repeat proteins but not neurodegeneration in BAC transgenic mice. Neuron 2015;88:902&#x2013;909.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4828340</ArticleId><ArticleId IdType="pubmed">26637797</ArticleId></ArticleIdList></Reference><Reference><Citation>Platt RJ, Chen S, Zhou Y, et al. CRISPR&#x2010;Cas9 knockin mice for genome editing and cancer modeling. Cell 2014;159:440&#x2013;455.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4265475</ArticleId><ArticleId IdType="pubmed">25263330</ArticleId></ArticleIdList></Reference><Reference><Citation>Stoica L, Todeasa SH, Toro Cabrera G, et al. AAV delivered artificial microRNA extends survival and delays paralysis in an amyotrophic lateral sclerosis mouse model. Ann Neurol 2016;79:687&#x2013;700.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5374859</ArticleId><ArticleId IdType="pubmed">26891182</ArticleId></ArticleIdList></Reference><Reference><Citation>Borel F, Gernoux G, Sun H, et al. Safe and effective superoxide dismutase 1 silencing using artificial microRNA in macaques. Sci Transl Med 2018;10:eaau6414.</Citation><ArticleIdList><ArticleId IdType="pubmed">30381409</ArticleId></ArticleIdList></Reference><Reference><Citation>Staub GC, Walton KM, Schnaar RL, et al. Characterization of the binding and internalization of tetanus toxin in a neuroblastoma hybrid cell line. J Neurosci 1986;6:1443&#x2013;1451.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6568566</ArticleId><ArticleId IdType="pubmed">3711989</ArticleId></ArticleIdList></Reference><Reference><Citation>MacKenzie CR, Hirama T, Lee KK, et al. Quantitative analysis of bacterial toxin affinity and specificity for glycolipid receptors by surface plasmon resonance. J Biol Chem 1997;272:5533&#x2013;5538.</Citation><ArticleIdList><ArticleId IdType="pubmed">9038159</ArticleId></ArticleIdList></Reference><Reference><Citation>Meckler RL, Baron R, McLachlan EM. Selective uptake of C&#x2010;fragment of tetanus toxin by sympathetic preganglionic nerve terminals. Neuroscience 1990;36:823&#x2013;829.</Citation><ArticleIdList><ArticleId IdType="pubmed">2234414</ArticleId></ArticleIdList></Reference><Reference><Citation>Hughes DI, Scott DT, Todd AJ, Riddell JS. Lack of evidence for sprouting of Abeta afferents into the superficial laminas of the spinal cord dorsal horn after nerve section. J Neurosci 2003;23:9491&#x2013;9499.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6740466</ArticleId><ArticleId IdType="pubmed">14573528</ArticleId></ArticleIdList></Reference><Reference><Citation>Herreros J, Lalli G, Schiavo G. C&#x2010;terminal half of tetanus toxin fragment C is sufficient for neuronal binding and interaction with a putative protein receptor. Biochem J 2000;347:199&#x2013;204.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1220948</ArticleId><ArticleId IdType="pubmed">10727419</ArticleId></ArticleIdList></Reference><Reference><Citation>Perreault MC, Pastor&#x2010;Bernier A, Renaud JS, et al. C fragment of tetanus toxin hybrid proteins evaluated for muscle&#x2010;specific transsynaptic mapping of spinal motor circuitry in the newborn mouse. Neuroscience 2006;141:803&#x2013;816.</Citation><ArticleIdList><ArticleId IdType="pubmed">16713105</ArticleId></ArticleIdList></Reference><Reference><Citation>Fil D, DeLoach A, Yadav S, et al. Mutant profilin1 transgenic mice recapitulate cardinal features of motor neuron disease. Hum Mol Genet 2017;26:686&#x2013;701.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5968635</ArticleId><ArticleId IdType="pubmed">28040732</ArticleId></ArticleIdList></Reference><Reference><Citation>Foust KD, Nurre E, Montgomery CL, et al. Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes. Nat Biotechnol 2009;27:59&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2895694</ArticleId><ArticleId IdType="pubmed">19098898</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharma A, Lyashchenko AK, Lu L, et al. ALS&#x2010;associated mutant FUS induces selective motor neuron degeneration through toxic gain of function. Nat Commun 2016;7:10465.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4742863</ArticleId><ArticleId IdType="pubmed">26842965</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanning KC, Kaplan A, Henderson CE. Motor neuron diversity in development and disease. Annu Rev Neurosci 2010;33:409&#x2013;440.</Citation><ArticleIdList><ArticleId IdType="pubmed">20367447</ArticleId></ArticleIdList></Reference><Reference><Citation>Schellingerhout D, Le Roux LG, Bredow S, Gelovani JG. Fluorescence imaging of fast retrograde axonal transport in living animals. Mol Imaging 2009;8:319&#x2013;329.</Citation><ArticleIdList><ArticleId IdType="pubmed">20003890</ArticleId></ArticleIdList></Reference><Reference><Citation>Fishman PS, Carrigan DR. Retrograde transneuronal transfer of the C&#x2010;fragment of tetanus toxin. Brain Res 1987;406:275&#x2013;279.</Citation><ArticleIdList><ArticleId IdType="pubmed">3567626</ArticleId></ArticleIdList></Reference><Reference><Citation>Pun S, Santos AF, Saxena S, et al. Selective vulnerability and pruning of phasic motoneuron axons in motoneuron disease alleviated by CNTF. Nat Neurosci 2006;9:408&#x2013;419.</Citation><ArticleIdList><ArticleId IdType="pubmed">16474388</ArticleId></ArticleIdList></Reference><Reference><Citation>Hegedus J, Putman CT, Gordon T. Time course of preferential motor unit loss in the SOD1 G93A mouse model of amyotrophic lateral sclerosis. Neurobiol Dis 2007;28:154&#x2013;164.</Citation><ArticleIdList><ArticleId IdType="pubmed">17766128</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin LJ, Liu Z, Chen K, et al. Motor neuron degeneration in amyotrophic lateral sclerosis mutant superoxide dismutase&#x2010;1 transgenic mice: mechanisms of mitochondriopathy and cell death. J Comp Neurol 2007;500:20&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pubmed">17099894</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomsen GM, Gowing G, Latter J, et al. Delayed disease onset and extended survival in the SOD1G93A rat model of amyotrophic lateral sclerosis after suppression of mutant SOD1 in the motor cortex. J Neurosci 2014;34:15587&#x2013;15600.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4298650</ArticleId><ArticleId IdType="pubmed">25411487</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaj T, Ojala DS, Ekman FK, et al. In vivo genome editing improves motor function and extends survival in a mouse model of ALS. Sci Adv 2017;3:eaar3952.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5738228</ArticleId><ArticleId IdType="pubmed">29279867</ArticleId></ArticleIdList></Reference><Reference><Citation>Kosicki M, Tomberg K, Bradley A. Repair of double&#x2010;strand breaks induced by CRISPR&#x2010;Cas9 leads to large deletions and complex rearrangements. Nat Biotechnol 2018;36:765&#x2013;771.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6390938</ArticleId><ArticleId IdType="pubmed">30010673</ArticleId></ArticleIdList></Reference><Reference><Citation>Valdez G, Tapia JC, Kang H, et al. Attenuation of age&#x2010;related changes in mouse neuromuscular synapses by caloric restriction and exercise. Proc Natl Acad Sci U S A 2010;107:14863&#x2013;14868.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2930485</ArticleId><ArticleId IdType="pubmed">20679195</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y, Lee Y, Thompson WJ. Changes in aging mouse neuromuscular junctions are explained by degeneration and regeneration of muscle fiber segments at the synapse. J Neurosci 2011;31:14910&#x2013;14919.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3213690</ArticleId><ArticleId IdType="pubmed">22016524</ArticleId></ArticleIdList></Reference><Reference><Citation>Valdez G, Tapia JC, Lichtman JW, et al. Shared resistance to aging and ALS in neuromuscular junctions of specific muscles. PLoS One 2012;7:e34640.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3317643</ArticleId><ArticleId IdType="pubmed">22485182</ArticleId></ArticleIdList></Reference><Reference><Citation>Fishman PS, Matthews CC, Parks DA, et al. Immunization does not interfere with uptake and transport by motor neurons of the binding fragment of tetanus toxin. J Neurosci Res 2006;83:1540&#x2013;1543.</Citation><ArticleIdList><ArticleId IdType="pubmed">16557581</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>